Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals reported FY2026 revenue of Rs. 2,872.25 million, up 6.9% from Rs. 2,687.16 million in FY2025. However, net profit declined significantly to Rs. 430.82 million from Rs. 553.61 million, a drop of approximately 22%. Profit before tax also fell to Rs. 575.18 million from Rs. 698.59 million in the prior year. The company declared a dividend of Rs. 4 per share (200%) for FY2026. During the year, the company recorded an exceptional item of Rs. 20.79 million due to new labour codes implementation. The statutory auditors, Walker Chandiok & Co. LLP, issued an unmodified (clean) audit opinion. The company also proposed a buyback of up to 1.6 million shares at Rs. 250 per share for an aggregate consideration not exceeding Rs. 400 million.
The stock may see mixed reaction as revenue growth is modest at 7% while profit declined 22%, indicating margin pressure despite higher sales. The dividend and share buyback announcement provide some shareholder returns. However, the significant profit decline warrants caution for investors focused on profitability.